Wird geladen...
A Paradigm Shift in Cancer Nanomedicine: From Traditional Tumor Targeting to Leveraging the Immune System
Twenty-five years after the approval of the first anticancer nanodrug, we have to start re(de)fining tumor-targeted drug delivery alongside advances in immuno-oncology. Because cancer is characterized by an immunological imbalance that goes beyond the primary tumor, we should focus on targeting, eng...
Gespeichert in:
| Veröffentlicht in: | Drug Discov Today |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7611945/ https://ncbi.nlm.nih.gov/pubmed/33617793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2021.02.017 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|